StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NAVB opened at $0.06 on Wednesday. Navidea Biopharmaceuticals has a one year low of $0.02 and a one year high of […]
Related Keywords
, Navidea Biopharmaceuticals Company Profile , Navidea Biopharmaceuticals Inc , Allred Capital Management , Renaissance Technologies , Therapeutic Development Programs , Navidea Biopharmaceuticals , Free Report , Get Free Report , Capital Management , Street Corp , Diagnostic Substances , Therapeutic Development , Navidea Biopharmaceuticals Daily , Nyse Navb , Navb , Medical , Initiated Coverage , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.